The European Life Sciences Web Portal
This is a free web portal for the life sciences in Europe and Israel... » read more
- Argen-X Gets €1.5m IWT Grant to Advance Antibody Technology (2015-05-19)
arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has received a € 1.5 mill...
- PsiOxus Raises a £25m Series C to Progress Oncolytic Virus (2015-05-19)
PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes from the anti...
- Abcodia: £5.25m Funding to Launch ROCA Ovarian Cancer Test (2015-05-18)
> Two new investors, Cambridge Innovative Capital and Scottish Equity Partners join existing investors Albion Ventures and UCLB > The investment enables the launch of the ROCA® test in US and UK in 2015, as well as the establishment of a US presence Abcodia...
- Galapagos Raises $275m Gross Proceeds with Nasdaq IPO (2015-05-14)
Galapagos NV (Euronext: GLPG) announced today the pricing of its global offering totaling $275 million gross proceeds of 6,550,000 new ordinary shares, consisting of 4,996,522 American Depositary Shares (“ADSs”) at $42.05 per ADS, and 1,553,478 ordinary shares at a...
- Danaher To Acquire Pall Corporation for $13.8b in Cash (2015-05-13)
Danaher Corporation (NYSE: DHR) ("Danaher") announced today that it has entered into a definitive merger agreement with Pall Corporation (NYSE: PLL) ("Pall") pursuant to which Danaher will acquire all of the outstanding shares of Pall for $127.20 per share in cash,...
- Danaher to Separate into Two Publicly Traded Companies (2015-05-13)
Danaher Corporation (NYSE:DHR) ("Danaher") today announced its intention to separate the company into two independent, publicly traded companies. The transaction will create: > A science and technology growth company united by common business model characteristi...
- Agilent Thought Leader Award for Jules Griffin in Cambridge (2015-05-12)
Agilent Technologies Inc. (NYSE: A) today announced that Jules Griffin has received an Agilent Thought Leader Award in recognition of his work in lipidomics. This award includes an Agilent 6560 Ion Mobility Q-TOF LC/MS system, which Dr. Griffin and his team will...
- BioNTech and Lilly Partner on Cancer Immunotherapies (2015-05-11)
Eli Lilly and Company (NYSE:LLY) and BioNTech AG today announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body's own immune system to attack cancer cells and create pos...
- Juno Therapeutics Acquires Stage Cell Therapeutics GmbH (2015-05-11)
> Transaction Provides Transformative Cell Selection and Activation Capabilities, Advanced Manufacturing Automation, Improved Supply Chain, and Lower Expected Cost of Goods > Initial Payment of €52.5 Million in Cash (Approximately $59 Million) and 486,279 Shares...
- NeuroVive Raises SEK70m in Private Placement [no US et al.] (2015-05-08)
NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, OMX:NVP) today announces that the Company has completed the directed share issue announced on May 7, 2015, whereby 1,647,059 new shares have been issued, which brings SEK 70 million to the Company be...
Life-Sciences-Europe.com is your doorway to the European life sciences!
[LSE] provides free, up-to-date and structured access to
in Europe and Israel.
Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSe] is 100% Made in Germany!Start here with the latest News!
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to email@example.com and simply fill the subject line with the word »LSE newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)